Surgery Plus Heated Chemo Is Extending Peritoneal Mesothelioma Survival. Here's What Patients Need to Know in 2026.
PHILADELPHIA, PA — Maria Delgado was 54 when her gastroenterologist finally stopped calling her symptoms irritable bowel syndrome. The bloating, the pressure, the fatigue that had shadowed her for nearly a year turned out to be something far more serious: peritoneal mesothelioma, a rare cancer of the abdominal lining almost always caused by asbestos exposure. Her oncologist at a regional cancer center told her the median survival was roughly one year. Then a second opinion changed everything.
That second opinion led Maria to a specialist who offered her a different path: cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, a procedure known as HIPEC. It's a grueling operation that can last eight to twelve hours. But for carefully selected patients, it has transformed peritoneal mesothelioma from a near-certain death sentence into a disease that some people survive for five years or longer. What I hear from patients going through this is that the hardest part isn't the surgery itself. It's the weeks before, when they're trying to decide whether to pursue an aggressive intervention at a specialized center far from home, or stay close to family and accept a more conservative approach.
This article is about that decision, and about what the latest evidence says for patients and families navigating it in 2026.
What Is the CRS-HIPEC Approach, and What Does the Evidence Show?
Cytoreductive surgery combined with HIPEC is a two-part procedure: surgeons first remove all visible tumor deposits from the abdominal cavity, then flood the surgical site with heated chemotherapy drugs, typically cisplatin, for 60 to 90 minutes. The heat amplifies the drugs' ability to penetrate tissue and kill residual cancer cells that the eye cannot see. According to a landmark study published in the Journal of Clinical Oncology, patients with peritoneal mesothelioma who underwent CRS-HIPEC at specialized centers achieved median overall survival of 53 months, compared to roughly 12 months for patients treated with systemic chemotherapy alone.
That figure, 53 months, is not a typo. It represents more than four years of median survival in a disease where, just two decades ago, most patients were told to get their affairs in order within twelve months. The same study, which analyzed outcomes at major U.S. and European centers, found that patients who achieved what surgeons call a complete cytoreduction, meaning no visible tumor remained after surgery, had a five-year survival rate approaching 50 percent. That's a number that would have been unthinkable when peritoneal mesothelioma was first characterized as a distinct disease entity.
The procedure isn't appropriate for everyone. Candidates typically need to be in good overall health, have disease confined to the abdominal cavity without spread to distant organs, and have what specialists describe as a low peritoneal cancer index, a scoring system that measures how extensively the tumor has spread across the abdominal surfaces. Patients with epithelioid cell type, the most common and least aggressive histology, tend to respond best. According to research published in the National Library of Medicine, epithelioid peritoneal mesothelioma carries meaningfully better outcomes than the biphasic or sarcomatoid subtypes, making histologic confirmation a critical first step in any treatment planning conversation.
For patients who want to understand the full landscape of peritoneal mesothelioma before their next appointment, knowing the cell type on your pathology report is one of the most important pieces of information you can bring to a specialist consultation.
Why This Matters Beyond the Operating Room
The survival data is compelling on its own. But the reason CRS-HIPEC has reshaped how specialists think about peritoneal mesothelioma goes beyond the numbers. It has forced a reclassification of the disease itself. Peritoneal mesothelioma, which accounts for roughly 20 to 30 percent of all mesothelioma diagnoses according to data from the National Cancer Institute, was historically lumped together with pleural mesothelioma in clinical conversations and even in some research protocols. The two diseases share a cause, asbestos, but they behave differently, respond differently to treatment, and increasingly require different specialists.
The emergence of CRS-HIPEC as a standard-of-care option at major cancer centers has driven the creation of dedicated peritoneal disease programs at institutions like Memorial Sloan Kettering Cancer Center in New York, Moffitt Cancer Center in Tampa, and the Mesothelioma and Pleural Disease Program at Brigham and Women's Hospital in Boston. These programs bring together surgical oncologists, medical oncologists, and pathologists who specialize specifically in peritoneal surface malignancies. According to Moffitt Cancer Center's mesothelioma program, multidisciplinary evaluation at a high-volume center is associated with better surgical outcomes, in part because the learning curve for CRS-HIPEC is steep and volume matters.
Many patients and families I've worked with don't realize that the surgeon's experience level with this specific procedure may matter as much as the procedure itself. A center that performs two or three HIPEC cases per year is a fundamentally different environment than one that performs fifty. Asking a potential surgeon directly about their annual case volume is not rude. It's essential.
"The most important step you can take right now is getting your pathology reviewed by a specialist who performs this surgery regularly. The first opinion isn't always the last word."
— Yvette Abrego, Patient Advocate
For veterans with peritoneal mesothelioma, navigating toward a specialized center can be particularly complicated. VA medical centers vary significantly in their oncology capabilities, and peritoneal mesothelioma specialists are concentrated at a handful of academic medical centers that may or may not be within the VA network. Veterans who believe their diagnosis stems from military asbestos exposure may also have access to VA benefits that can offset the cost of traveling to a specialized center, and understanding those benefits early can make the logistical difference.
How Does CRS-HIPEC Compare to Systemic Chemotherapy?
For years, the standard first-line treatment for peritoneal mesothelioma was the same combination used for pleural disease: pemetrexed plus cisplatin, a regimen the FDA approved under the brand name Alimta in 2004. That approval was based on trials that included both pleural and peritoneal patients, and pemetrexed-based chemotherapy remains an important tool, particularly for patients who aren't surgical candidates or who experience recurrence after surgery.
But the comparison between systemic chemotherapy and CRS-HIPEC is stark for eligible patients. The Journal of Clinical Oncology data shows a median survival difference measured in years, not months. Researchers have also noted that systemic chemotherapy for peritoneal disease faces a fundamental pharmacologic challenge: the peritoneum has its own barrier properties that limit how much drug actually reaches the tumor from the bloodstream. HIPEC bypasses that barrier entirely by delivering chemotherapy directly to the source.
The chemotherapy options for mesothelioma have expanded in recent years with the addition of immunotherapy combinations, and some peritoneal patients are now receiving nivolumab plus ipilimumab or bevacizumab-containing regimens as part of clinical trials or off-label protocols. Memorial Sloan Kettering's mesothelioma program has been at the forefront of integrating immunotherapy into peritoneal disease treatment, and early data from combination approaches is generating interest in the field. According to the NCI clinical trials database, multiple trials are actively recruiting peritoneal mesothelioma patients in 2026 to evaluate immunotherapy in combination with or following CRS-HIPEC.
The picture is still evolving. What's clear is that a patient who was told in 2015 that their only option was palliative chemotherapy might, in 2026, be a candidate for a curative-intent surgical approach followed by immunotherapy maintenance. The landscape has changed that significantly.
What Role Do Biomarkers Play in Treatment Selection?
One of the more consequential developments in peritoneal mesothelioma care over the past several years has been the growing role of molecular biomarkers in guiding treatment decisions. A 2021 study published in the National Library of Medicine examined the utility of biomarkers including BRCA1-associated protein 1 (BAP1) and fibulin-3 in early detection and risk stratification of mesothelioma patients. BAP1 mutation status, in particular, has emerged as a marker with implications not just for diagnosis but for prognosis and potentially for treatment selection.
Patients with BAP1-mutated tumors appear to have more favorable outcomes after CRS-HIPEC in some analyses, though the data is still maturing. More broadly, the push toward molecular profiling of mesothelioma tumors reflects a shift in how oncologists think about the disease: not as a single entity defined by its anatomic location, but as a collection of molecularly distinct subtypes that may respond differently to different interventions.
For patients, this means that a comprehensive pathology workup, one that goes beyond simply confirming the diagnosis to actually characterizing the tumor's molecular profile, is increasingly valuable before making treatment decisions. Major centers like Brigham and Women's Hospital and Memorial Sloan Kettering routinely perform extended molecular panels on peritoneal mesothelioma specimens. If your initial pathology was done at a community hospital, requesting that tissue be sent to a specialized center for re-review is a reasonable and often consequential step.
According to researchers at the National Cancer Institute, early biomarker detection could eventually allow for intervention before mesothelioma becomes symptomatic in high-risk individuals, particularly those with known asbestos exposure histories. That remains a future goal rather than a current clinical reality, but it underscores the direction the field is moving.
What Should Patients and Families Do Next?
A composite scenario I return to often: a 58-year-old man in Phoenix receives a peritoneal mesothelioma diagnosis at a community oncology practice. His oncologist is skilled and caring, but has treated perhaps three mesothelioma patients in a career. He's told that chemotherapy is the standard approach. His family starts researching online at midnight and finds references to HIPEC but isn't sure if it's real, experimental, or relevant to his situation. Three weeks pass. Then a month.
Time matters in peritoneal mesothelioma, but not in the way that should cause panic. It matters because the window for surgical candidacy can close if disease progresses significantly, and because delays in reaching a specialist can mean the difference between being offered a curative-intent approach and being told the disease has advanced beyond what surgery can address. The most important step you can take right now, if you or someone you love has received this diagnosis, is to request a consultation at a center with a dedicated peritoneal disease or mesothelioma program.
Here's what that process looks like in practice. First, request copies of all pathology slides and reports, not just the written summary. Specialized centers will want to review the actual tissue. Second, gather all imaging, CT scans and PET scans, on a disc or through a digital transfer. Third, contact the mesothelioma program directly, not through a general referral line. Many major centers have nurse navigators or patient coordinators who specialize in mesothelioma and can expedite the intake process.
For patients exploring clinical trials, the NCI's clinical trials search database is a legitimate starting point, and California alone has multiple actively recruiting mesothelioma trials in 2026 according to ClinicalTrials.gov. Patients who were exposed to asbestos in occupational settings may also have access to financial compensation through asbestos trust funds or litigation, which can help offset the significant costs of traveling to a specialized center or taking extended time away from work. The trust fund checker tool is a free resource that can help identify whether a patient's exposure history aligns with any of the more than 60 active asbestos bankruptcy trusts.
Veterans facing this diagnosis have additional resources available through the VA system, and a VA benefits eligibility check can clarify what's available before the first specialist appointment. Understanding the financial picture early removes one barrier to pursuing the most aggressive and appropriate treatment.
The Surgical Debate: What Happens When CRS-HIPEC Isn't the Right Fit?
Not every peritoneal mesothelioma patient is a HIPEC candidate, and it's worth being direct about what that means. Patients with extensive disease spread, poor performance status, or significant cardiac or renal comorbidities may not safely tolerate a surgery that can involve removing portions of the bowel, spleen, portions of the diaphragm, and other abdominal structures in addition to the tumor debulking itself. For these patients, systemic therapy remains the primary approach, and the immunotherapy combinations now entering the peritoneal mesothelioma space offer genuine hope where previously there was very little.
According to research from the National Library of Medicine comparing surgical approaches in pleural mesothelioma, the principle of patient selection is paramount. The same principle applies in the peritoneal setting: the goal is not to operate on every patient, but to identify those most likely to benefit and spare others from a morbid procedure that won't change their outcome. Surgeons at high-volume centers are generally frank about this. A specialist who tells a patient they are not a surgical candidate is not giving up. They are making a judgment that protects the patient from unnecessary harm.
For patients in this category, clinical trial enrollment is particularly worth pursuing. The immunotherapy landscape for mesothelioma has expanded considerably since the FDA's 2020 approval of nivolumab plus ipilimumab for pleural disease, and researchers are actively working to extend those findings to the peritoneal setting. Patients interested in exploring trial options can search by location and disease type through the NCI database, or ask their oncologist to consult with a mesothelioma specialist about available protocols.
If you're uncertain about your legal options alongside your medical ones, the legal answers section of this site provides plain-language guidance on what mesothelioma patients are typically entitled to pursue, and the lawyer directory connects patients with attorneys who specialize specifically in asbestos-related claims. Many patients don't realize that pursuing compensation doesn't require a lawsuit and doesn't interfere with treatment.
Looking Ahead: Where Peritoneal Mesothelioma Research Is Heading
The trajectory of peritoneal mesothelioma research in 2026 is pointed toward three areas: refining patient selection for CRS-HIPEC using molecular profiling, integrating immunotherapy into the perioperative setting, and developing earlier detection tools that could identify the disease before it becomes surgically unmanageable.
Researchers at Moffitt Cancer Center and Memorial Sloan Kettering are among those studying whether immunotherapy given before surgery, in what oncologists call the neoadjuvant setting, can downstage tumors enough to make previously ineligible patients into surgical candidates. Early results from small series are cautiously encouraging. The Nature mesothelioma research portal catalogs ongoing work in this space, and the pace of publication has accelerated meaningfully over the past three years.
What I hear from patients going through this is that the research pace feels both encouraging and frustrating. Encouraging because the field is clearly moving. Frustrating because the trials that might help them are sometimes only available at a handful of centers, or have eligibility criteria that exclude patients with prior treatment. Navigating that landscape is genuinely hard, and it's one reason why connecting with a patient advocate or a mesothelioma nurse navigator early in the process makes a concrete difference.
The story of peritoneal mesothelioma in 2026 is not a story of a cure. It's a story of a disease being slowly, methodically pushed back by surgeons and oncologists who refused to accept that nothing could be done. For patients like Maria Delgado, that stubbornness has meant years with her family that she was told she wouldn't have. That represents the result of specialized care, careful patient selection, and the willingness to travel to the right center at the right time.
Frequently Asked Questions
What is HIPEC and how is it used to treat peritoneal mesothelioma?
HIPEC stands for hyperthermic intraperitoneal chemotherapy. It is delivered directly into the abdominal cavity during surgery, immediately after surgeons have removed all visible tumor deposits. The chemotherapy is heated to approximately 42 degrees Celsius, which enhances its ability to penetrate tissue and destroy residual cancer cells. According to a study in the Journal of Clinical Oncology, patients treated with CRS-HIPEC at specialized centers achieved median survival exceeding 53 months.
Who is a candidate for cytoreductive surgery with HIPEC?
Ideal candidates are patients with peritoneal mesothelioma confined to the abdominal cavity, good overall performance status, epithelioid cell type, and a low peritoneal cancer index score. Patients with distant metastases, significant organ dysfunction, or extensive abdominal spread are generally not surgical candidates. Eligibility is determined through multidisciplinary evaluation at a specialized center, typically including review of imaging, pathology, and a thorough medical assessment.
How does peritoneal mesothelioma differ from pleural mesothelioma in terms of treatment?
Pleural mesothelioma affects the lung lining and is treated primarily with surgery, chemotherapy, and immunotherapy. Peritoneal mesothelioma affects the abdominal lining and has a distinct treatment approach centered on CRS-HIPEC for eligible patients. According to the National Cancer Institute, peritoneal mesothelioma accounts for 20 to 30 percent of all mesothelioma diagnoses and has different prognostic factors and surgical considerations than the pleural form.
What chemotherapy drugs are used in HIPEC for mesothelioma?
Cisplatin is the most commonly used agent in HIPEC for peritoneal mesothelioma, sometimes combined with doxorubicin or mitomycin C depending on the center's protocol. Systemic chemotherapy with pemetrexed, marketed as Alimta and FDA-approved for mesothelioma in 2004, remains a standard option for patients who are not surgical candidates or who experience recurrence after CRS-HIPEC.
Can veterans with peritoneal mesothelioma access specialized treatment through the VA?
Veterans can access VA benefits to help cover mesothelioma treatment costs, but peritoneal mesothelioma specialists are concentrated at academic medical centers that may require travel. Veterans may be eligible for VA travel benefits and community care referrals that allow treatment outside the VA system. Using a VA benefits eligibility tool early in the process helps clarify what's available before the first specialist consultation.
How important is it to get a second opinion for peritoneal mesothelioma?
Getting a second opinion at a high-volume mesothelioma center is widely considered essential by specialists in the field. Community oncologists may have limited experience with peritoneal mesothelioma specifically, and treatment recommendations can differ significantly between general oncology practices and dedicated peritoneal disease programs. Requesting that pathology slides be reviewed by a specialist at a major center is a low-risk step that can meaningfully change the treatment plan.
Are there clinical trials available for peritoneal mesothelioma patients in 2026?
Yes. Multiple clinical trials are actively recruiting peritoneal mesothelioma patients in 2026, including studies evaluating immunotherapy combinations, neoadjuvant approaches before surgery, and novel agents. The NCI clinical trials search database allows patients to search by disease type, location, and trial status. California alone has several actively recruiting mesothelioma trials according to ClinicalTrials.gov's current listings.
This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider for guidance specific to your situation.